186 related articles for article (PubMed ID: 18361409)
1. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
Morgan TM; Pitts TE; Gross TS; Poliachik SL; Vessella RL; Corey E
Prostate; 2008 Jun; 68(8):861-71. PubMed ID: 18361409
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis MG; Shultz LD; Mönkkönen J; Rédini F; Heymann D
Cancer Res; 2010 Dec; 70(24):10329-39. PubMed ID: 20971812
[TBL] [Abstract][Full Text] [Related]
3. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
4. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Pan Y; Jin H; Chen W; Yu Z; Ye T; Zheng Y; Weng Z; Wang F
Int Urol Nephrol; 2014 Dec; 46(12):2319-26. PubMed ID: 25224665
[TBL] [Abstract][Full Text] [Related]
6. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
[TBL] [Abstract][Full Text] [Related]
8. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
9. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
[TBL] [Abstract][Full Text] [Related]
10. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
Hjelmeland AB; Lattimore KP; Fee BE; Shi Q; Wickman S; Keir ST; Hjelmeland MD; Batt D; Bigner DD; Friedman HS; Rich JN
Mol Cancer Ther; 2007 Sep; 6(9):2449-57. PubMed ID: 17766837
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
[TBL] [Abstract][Full Text] [Related]
12. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
Juengel E; Engler J; Natsheh I; Jones J; Mickuckyte A; Hudak L; Jonas D; Blaheta RA
BMC Cancer; 2009 May; 9():161. PubMed ID: 19473483
[TBL] [Abstract][Full Text] [Related]
13. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
14. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
[TBL] [Abstract][Full Text] [Related]
15. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
[TBL] [Abstract][Full Text] [Related]
17. Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis.
Yu Y; Song Z; Yang S; Yang X; Zhang J; Lu S
Acta Biochim Biophys Sin (Shanghai); 2014 Sep; 46(9):792-801. PubMed ID: 25098623
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Fabbri F; Brigliadori G; Carloni S; Ulivi P; Vannini I; Tesei A; Silvestrini R; Amadori D; Zoli W
J Transl Med; 2008 Aug; 6():43. PubMed ID: 18691406
[TBL] [Abstract][Full Text] [Related]
19. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.
Kirk PS; Koreckij T; Nguyen HM; Brown LG; Snyder LA; Vessella RL; Corey E
Int J Mol Sci; 2013 May; 14(5):10483-96. PubMed ID: 23698775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
